Chronic Lymphocytic Leukemia (CLL) was one of the hot topics at this year’s annual meeting of the American Society of Hematology (ASH), and a new CLL drug that caught my attention was the second-generation Bruton’s Tyrosine Kinase (BTK) inhibitor ONO-4059 from Ono Pharmaceuticals.

Professor Gilles Salles (Lyon, France) presented promising efficacy data from a phase 1 study of ONO-4059 in relapsed/refractory CLL and high risk CLL (#676).

Unfortunately after his presentation, Prof Salles declined my request for a quick interview citing a prior commitment with a large pharma company and subsequently failed to turn up for an agreed interview the next day. Talking about ONO-4059, at least with the media, did not appear to be a priority!

However, as a potential competitor to other BTK inhibitors in development such as ibrutinib (Pharmacyclics/JNJ) and CC-292 (Celgene/Avila) it’s worthy of a mention in the conference coverage and a quick post about the data presented.

Premium subscribers and those interested in signing up for the conference coverage service can click on the link in the box below to access the post.

 ASH 2013: New BTK Inhibitor ONO 4059 shows early promise in CLL   is it a future competitor to ibrutinib?

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $129 a month (THIS SUBSCRIPTION AUTOMATICALLY BILLS YOUR CREDIT CARD EACH MONTH UNTIL YOU CANCEL) or $327 for 3 months access (does not auto renew), $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if a communications professional our Guidance to PR Professionals contained within it.